Dr. Carlos Ramos, MD
Claim this profileHouston Methodist Hospital
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
9 reported clinical trials
13 drugs studied
Area of expertise
1Lymphoma
CD30 positive
CD30CAR positive
ALK negative
2Non-Hodgkin's Lymphoma
CD19 positive
CD30 positive
CD19.CAR positive
Affiliated Hospitals
Clinical Trials Carlos Ramos, MD is currently running
CD19.CAR-aNKT Cells
for Lymphoma and Leukemia
This study is for patients who have lymphoma or leukemia that has come back or has not gone away after treatment. Because there is no standard treatment for this cancer, patients are being asked to volunteer for a gene transfer research study using special immune cells. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting disease, antibodies and immune cells. Antibodies are types of proteins that protect the body from bacteria and other diseases. Immune cells, also called lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. Both antibodies and lymphocytes have been used to treat patients with cancer. They have shown promise, but have not been strong enough to cure most patients. The antibody used in this study is called anti-CD19. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD19. CD19 antibodies have been used to treat people with lymphoma and leukemia. For this study, the anti-CD19 antibody has been changed so that instead of floating free in the blood it is now joined to the NKT cells, a special type of lymphocytes that can kill tumor cells but not very effectively on their own. When an antibody is joined to a T cell in this way it is called a chimeric receptor. Investigators have also found that NKT cells work better if proteins are added that stimulate lymphocytes, such as one called CD28. Adding the CD28 makes the cells last for a longer time in the body but maybe not long enough for them to be able to kill the lymphoma cells. It is believed that by adding an extra stimulating protein, called IL-15, the cells will have an even better chance of killing the lymphoma cells. In this study the investigators are going to see if this is true by putting the anti-CD19 chimeric receptor with CD28 and the IL-15 into NKT cells grown from a healthy individual. These cells are called ANCHOR cells. These cells will be infused into patients that have lymphomas or leukemias that have CD19 on their surface. The ANCHOR cells are investigational products not approved by the Food and Drug Administration. The purpose of this study is to find the biggest dose of ANCHOR cells that is safe, to see how long the ANCHOR cells last, to learn what their side effects are and to see whether this therapy might help people with lymphoma or leukemia.
Recruiting1 award Phase 114 criteria
CAR T-cell Therapy
for Lymphoma
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, the patients are being asked to volunteer in this research study. In this study the investigators want to test a type of T cell made from a normal donor. The T cells the investigators will use are called Epstein Barr virus (EBV) specific T cells (EBVSTs) and are cells that the investigators have trained in the laboratory to recognize a EBV which is the virus that causes mono or kissing disease. Some patients with lymphoma have EBV in their cancer cells. Researchers have given T cell lines from normal donor EBVSTs to lymphoma patients who have EBV in their lymphoma cells and have seen responses in about half the patients. The cells have have been generated and are frozen in a bank. The cells are called "allogeneic" (meaning the donor is not related to the patient). CD30.CAR in EBV-specific T cells (called allogeneic CD30.CAR-EBVST) from the blood of healthy donors. The investigators are giving the cells to patients with lymphoma cells that express CD30. If the lymphoma cells also express EBV there may be some benefit from targeting both proteins. The purpose of this study is to find out the highest safe dose of allogeneic CD30.CAR-EBVST cells given following chemotherapy and used to treat lymphoma. The investigators will learn the side effects of CD30.CAR-EBVST cells in patients and see whether this therapy may help lymphoma patients
Recruiting1 award Phase 11 criteria
More about Carlos Ramos, MD
Clinical Trial Related2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Carlos Ramos, MD has experience with
- Fludarabine
- Cyclophosphamide
- Nivolumab
- CD30.CAR-EBVST Cells
- CD30.CAR-T
- CD19.CAR/28 And CD19.CAR/28137 T Cells
Breakdown of trials Carlos Ramos, MD has run
Lymphoma
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carlos Ramos, MD specialize in?
Carlos Ramos, MD focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved CD30 positive patients, or patients who are CD30CAR positive.
Is Carlos Ramos, MD currently recruiting for clinical trials?
Yes, Carlos Ramos, MD is currently recruiting for 5 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Carlos Ramos, MD has studied deeply?
Yes, Carlos Ramos, MD has studied treatments such as Fludarabine, Cyclophosphamide, Nivolumab.
What is the best way to schedule an appointment with Carlos Ramos, MD?
Apply for one of the trials that Carlos Ramos, MD is conducting.
What is the office address of Carlos Ramos, MD?
The office of Carlos Ramos, MD is located at: Houston Methodist Hospital, Houston, Texas 77030 United States. This is the address for their practice at the Houston Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.